Literature DB >> 32862879

Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma - Moving Toward a Personalized Approach.

Shakira J Grant1, Brea Lipe2.   

Abstract

CASE VIGNETTE: A 75-year-old male undergoes an evaluation for progressively worsening fatigue with associated shortness of breath. He also reports back pain worse at night, which does not resolve with acetaminophen. He is retired, but over the past 2 months he is unable to garden or perform household chores. Due to his pain and fatigue, he has limited his activity. He currently takes 9 prescription medications for chronic medical conditions, which include diabetes mellitus with neuropathy, hypertension, hyperlipidemia, and COPD. Initial evaluation reveals anemia (Hgb 9.0 g/dl last known normal was 2 years ago, Hgb 13.5 g/dl), renal impairment (serum creatinine 2.5 mg/dL), hypercalcemia (11.5 g/dl). Plain X-rays reveal compression fractures involving T3 and T4. Multiple myeloma is suspected, further labs confirm the diagnosis of IgG kappa multiple myeloma. LDH is elevated, beta-2-microglobulin is elevated at 6.1 mg/L and albumin < 3.5 mg/dl. Bone marrow aspiration and biopsy reveal plasmacytosis of 55% and on fluorescence in situ hybridization testing, del 17p/TP53 mutation in 85% of cells is detected. PET/CT confirms diffuse bone disease involving the axial and appendicular skeleton. His Karnofsky performance status (KPS) is 70%. He is widowed and lives alone but has 2 adult children who currently live out of state. This abstract will discuss how assessments of fitness/frailty may be used to develop personalized care tailored to the unique needs of older frail adults with multiple myeloma.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Frailty; geriatric assessment; multiple myeloma; older adults

Mesh:

Year:  2020        PMID: 32862879      PMCID: PMC8931508          DOI: 10.1016/S2152-2650(20)30470-5

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  23 in total

1.  Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

Authors:  Joseph Mikhael; Nofisat Ismaila; Matthew C Cheung; Caitlin Costello; Madhav V Dhodapkar; Shaji Kumar; Martha Lacy; Brea Lipe; Richard F Little; Anna Nikonova; James Omel; Namrata Peswani; Anca Prica; Noopur Raje; Rahul Seth; David H Vesole; Irwin Walker; Alexander Whitley; Tanya M Wildes; Sandy W Wong; Tom Martin
Journal:  J Clin Oncol       Date:  2019-04-01       Impact factor: 44.544

2.  Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Authors:  Thierry Facon; Shaji Kumar; Torben Plesner; Robert Z Orlowski; Philippe Moreau; Nizar Bahlis; Supratik Basu; Hareth Nahi; Cyrille Hulin; Hang Quach; Hartmut Goldschmidt; Michael O'Dwyer; Aurore Perrot; Christopher P Venner; Katja Weisel; Joseph R Mace; Noopur Raje; Michel Attal; Mourad Tiab; Margaret Macro; Laurent Frenzel; Xavier Leleu; Tahamtan Ahmadi; Christopher Chiu; Jianping Wang; Rian Van Rampelbergh; Clarissa M Uhlar; Rachel Kobos; Ming Qi; Saad Z Usmani
Journal:  N Engl J Med       Date:  2019-05-30       Impact factor: 91.245

3.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

4.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Authors:  María-Victoria Mateos; Meletios A Dimopoulos; Michele Cavo; Kenshi Suzuki; Andrzej Jakubowiak; Stefan Knop; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Polina Kaplan; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna M Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Iosava; Tomoaki Fujisaki; Mamta Garg; Christopher Chiu; Jianping Wang; Robin Carson; Wendy Crist; William Deraedt; Huong Nguyen; Ming Qi; Jesus San-Miguel
Journal:  N Engl J Med       Date:  2017-12-12       Impact factor: 91.245

5.  Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology.

Authors:  Supriya G Mohile; William Dale; Mark R Somerfield; Mara A Schonberg; Cynthia M Boyd; Peggy S Burhenn; Beverly Canin; Harvey Jay Cohen; Holly M Holmes; Judith O Hopkins; Michelle C Janelsins; Alok A Khorana; Heidi D Klepin; Stuart M Lichtman; Karen M Mustian; William P Tew; Arti Hurria
Journal:  J Clin Oncol       Date:  2018-05-21       Impact factor: 44.544

6.  Prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: report from the Canadian study of health and aging.

Authors:  Kenneth Rockwood; Susan E Howlett; Chris MacKnight; B Lynn Beattie; Howard Bergman; Réjean Hébert; David B Hogan; Christina Wolfson; Ian McDowell
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2004-12       Impact factor: 6.053

Review 7.  Elderly patients with multiple myeloma: towards a frailty approach?

Authors:  Sonja Zweegman; Monika Engelhardt; Alessandra Larocca
Journal:  Curr Opin Oncol       Date:  2017-09       Impact factor: 3.645

8.  A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.

Authors:  Monika Engelhardt; Anne-Saskia Domm; Sandra Maria Dold; Gabriele Ihorst; Heike Reinhardt; Alexander Zober; Stefanie Hieke; Corine Baayen; Stefan Jürgen Müller; Hermann Einsele; Pieter Sonneveld; Ola Landgren; Martin Schumacher; Ralph Wäsch
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

9.  Incidence and survival of hematological cancers among adults ages ≥75 years.

Authors:  Jessica L Krok-Schoen; James L Fisher; Julie A Stephens; Alice Mims; Sabarish Ayyappan; Jennifer A Woyach; Ashley E Rosko
Journal:  Cancer Med       Date:  2018-04-13       Impact factor: 4.452

10.  Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age.

Authors:  Monika Engelhardt; Gabriele Ihorst; Jesus Duque-Afonso; Ulrich Wedding; Ernst Spät-Schwalbe; Valentin Goede; Gerald Kolb; Reinhard Stauder; Ralph Wäsch
Journal:  Haematologica       Date:  2020-04-02       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.